Back to search
Plasma Cell Disorders
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Plasma Cell Disorders trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Plasma Cell Disorders trials you may qualify forBackground: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are st…
The purpose of this study is to assess the safety of teclistamab in routine clinical practice when given as monotherapy in Indian participants with relapsed and…
This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BC…
The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing t…
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer tha…
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
Background: Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatment (relapse) in almost all people; MM may…
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide rela…